A red flag is a fact that should change what you do next. In 2026 the facts that matter in a pharmacy come from three places: the prescription in front of you, the count in your vault, and the people who have keys to it. This guide sorts the red flags by those three sources, ties each to the federal rule that makes it matter, and notes two 2026 developments that change how some of them are treated: the telemedicine extension and a Fifth Circuit decision on pharmacist liability.

What the rules actually say, and what they leave out

No federal regulation contains a list of red flags. The only text is the corresponding-responsibility rule, 21 CFR 1306.04(a). It says a prescription for a controlled substance must be "issued for a legitimate medical purpose" by a practitioner "acting in the usual course of his professional practice," and that the responsibility for proper prescribing and dispensing is on the prescriber, "but a corresponding responsibility rests with the pharmacist who fills the prescription" (eCFR, 21 CFR 1306.04). Everything else called a red flag comes from enforcement decisions, agency guidance and case law. Commentary on that material describes the lists as non-exhaustive and gives examples such as cash payment, long travel distances and signs of doctor shopping (American Pharmacists Association commentary).

The practical consequence is that you cannot treat a checklist from any website, including this one, as a legal safe harbor. What you can do is decide in advance which observations your pharmacy treats as stop signs, who resolves them, and where the resolution is written down. The rest of this guide helps with the first of those three.

Red flags at the counter: the prescription and the patient

These are the flags that touch corresponding responsibility directly. Treat any of them as a reason to pause and verify before dispensing, not as proof of wrongdoing.

  • Pattern, not instance. One early refill is a question. The same early refill across a prescriber's whole panel is a pattern. Run a monthly report of controlled-substance fills by prescriber so that a pattern shows up in data instead of in a pharmacist's memory.
  • High-risk combinations. A recent legal analysis names three kinds of fact courts have treated as raising reasonable suspicion: unusual prescription volume, suspicious handwriting, and high-risk drug combinations (Harris Beach Murtha, Fifth Circuit analysis). An opioid filled together with a benzodiazepine is the familiar example of the last.
  • Unusual volume. A prescriber whose scripts are most of your Schedule II volume, or a day when your own volume doubles, deserves a look at who sent the patients and why.
  • Payment and distance. Cash for a high-cost controlled substance, and patients traveling far past other pharmacies, are both cited in the commentary above as commonly raised flags.
  • Forged or altered paper. Handwriting that differs between lines, quantities that look overwritten, or a prescriber who cannot be reached at the number on the script. Our guide to e-prescription fraud covers the electronic version.

Whatever you decide, write it down. The APhA commentary linked above reports a DEA enforcement action in which the expectation was that a pharmacist's resolution of a red flag be documented, and a flag that is resolved but unrecorded is, for an inspector, indistinguishable from one that was ignored. Our corresponding responsibility guide explains the duty in more detail.

A 2026 caveat: the Fifth Circuit's Neumann's Pharmacy decision

On February 13, 2026, the Fifth Circuit decided Neumann's Pharmacy, L.L.C. v. DEA (No. 25-60068). According to the Harris Beach Murtha analysis, the court rejected the agency's long-standing "knows or has reason to know" reading and held that federal liability "arises only based on actual knowledge that a prescription was invalid at the time it was dispensed," while keeping willful blindness as a valid basis because it is a "subjective state of mind." The same analysis states that the ruling does not change pharmacists' duties under state law and addresses only the Fifth Circuit.

Read that carefully before changing anything. A pharmacy in the Fifth Circuit should ask counsel how the ruling affects its federal exposure. A pharmacy anywhere else has no reason to loosen a single red-flag procedure, and no pharmacy should read the decision as permission to look away: willful blindness is the doctrine under which a deliberate decision not to examine a flagged prescription can count as knowledge. Your state board still applies its own standard, and our state pages link each board's rules.

Red flags in the vault: counts, losses and records

The second source of red flags is the stock itself. The regulations here are specific, so these flags are easier to define than the prescription ones.

  • An unexplained loss. Under 21 CFR 1301.76(b), a registrant must notify the DEA Field Division Office in writing of the theft or significant loss of controlled substances "within one business day of discovery," and must file a complete DEA Form 106 within 45 days (eCFR, 21 CFR 1301.76). A discrepancy that stays open past the point where you can still explain it is a red flag about your own process. See the Form 106 guide and the preliminary notification explainer.
  • A count that is always off in the same direction. Random error tends to net out across a quarter; theft does not. Trend each drug's variance by sign, not only by magnitude. Our perpetual inventory pitfalls guide lists ways a running balance can mask this.
  • An inventory you could not defend. 21 CFR 1304.11 requires a complete and accurate inventory at least every two years, with the opening-or-close-of-business time indicated, an exact count for Schedule II containers and, for opened Schedule III-V containers, an estimated count unless the container holds more than 1,000 units (eCFR, 21 CFR 1304.11). A missing or undated inventory is a red flag on its own.
  • Records you cannot produce. 21 CFR 1304.04 requires at least two years of retention, and pharmacies must keep Schedule I and II records apart from other records (eCFR, 21 CFR 1304.04).

Red flags in the staff: access and behavior

Employee diversion is the category most pharmacies underweight, because it requires suspecting a colleague. Two rules frame it. 21 CFR 1301.76(a) bars employing, in a role with access to controlled substances, a person who has been convicted of a felony relating to controlled substances or who has had a DEA registration denied, revoked or surrendered for cause. And 21 CFR 1301.91 places on an employee who knows of a coworker's diversion an obligation to report it to a responsible security official, requires the employer to keep the report confidential, and requires the employer to tell all employees of the policy (eCFR, 21 CFR 1301.91).

The second rule is easy to miss. If you have not told your staff that they must report, your program has a gap before any diversion happens. The observable flags to pair with it are the ones our signs of medication diversion guide lists, such as being the person who always handles the safe, resisting leave, and a count that goes wrong on one person's shifts. None is proof; each is a reason to compare that person's numbers with their peers'. The public case registry on this site shows how such cases played out, and the penalty outcomes page shows what followed.

A 2026 caveat: telemedicine prescriptions

The DEA and HHS issued a fourth temporary extension of the COVID-era telemedicine flexibilities, published in the Federal Register on December 31, 2025, effective January 1, 2026 through December 31, 2026 (90 FR 61301, FR Doc. 2025-24123). Under it, practitioners may continue to prescribe controlled substances after an audio-video visit without a prior in-person evaluation, so a telemedicine origin is not itself a red flag this year. The flag is the combination: a prescriber you cannot verify, a state license that does not match the patient's location, or a volume pattern from one telehealth source. Our telehealth prescribing guide covers the verification steps. Because the rule is temporary, put the December 31, 2026 date on your compliance calendar.

Turning red flags into a routine

A list does not reduce diversion; a routine does. Assign each red flag an owner, a frequency and a place where its resolution is recorded. Prescription flags belong to the pharmacist in charge at the time of dispensing. Count flags belong to whoever reconciles, reviewed by someone who does not. Staff flags belong to a named person outside the day-to-day chain, so an employee can report under 1301.91 without reporting to the person concerned. Then test the routine: ask a technician where they would go with a concern, and check the answer matches the policy.

To see which of these routines your pharmacy has and which are missing, run the community pharmacy self-assessment. It scores the same three areas covered here.

Sources: 21 CFR 1301.76, 1301.91, 1304.04, 1304.11 and 1306.04 (eCFR, current); Federal Register Vol. 90, No. 247 (Dec. 31, 2025), FR Doc. 2025-24123; Harris Beach Murtha analysis of Neumann's Pharmacy, L.L.C. v. DEA, No. 25-60068 (5th Cir. Feb. 13, 2026); APhA commentary on documenting red-flag resolution.